Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Reviva Pharmaceuticals Holdings Inc RVPH

Healthcare Biotechnology
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications,... see more

Recent & Breaking News (NDAQ:RVPH)

Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewswire 13 hours ago

Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine's Potential Across Multiple Neuropsychiatric Indications

GlobeNewswire April 23, 2026

Reviva Announces Letter to Shareholders

GlobeNewswire April 15, 2026

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

GlobeNewswire March 30, 2026

Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering

GlobeNewswire March 23, 2026

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

GlobeNewswire March 18, 2026

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

GlobeNewswire March 18, 2026

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

GlobeNewswire January 8, 2026

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

GlobeNewswire December 29, 2025

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

GlobeNewswire December 23, 2025

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire November 13, 2025

Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025

GlobeNewswire November 12, 2025

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis

GlobeNewswire November 10, 2025

Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference

GlobeNewswire October 29, 2025

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

GlobeNewswire October 28, 2025

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

GlobeNewswire October 7, 2025

Reviva to Participate in the 4th Annual Roth Healthcare Opportunities Conference

GlobeNewswire October 2, 2025

Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference

GlobeNewswire September 23, 2025

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

GlobeNewswire September 18, 2025

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

GlobeNewswire September 18, 2025

Podcasts